| Disease | THE STUDY WAS SUPPOSED TO INVESTIGATE A POSSIBLE PREVENTION OR REDUCTION OF THE TOXICITY OF RADIOTHERAPY BY AN ADDITIONAL TREATMENT WITH ESBERITOX. THIS QUESTION ARISES WHEN PERFORMING AN INVESTIGATION ABOUT THE EFFECT OF ESBERITOX IN A COMBINED
CHEMO-RADIOTHERAPY. WHEREAS THE LATTER INDUCED ABOVE ALL A SYSTEMIC DAMAGE TO THE HEMOPOIETIC SYSTEM, RADIOTHERAPY IS A REGIONAL NOXA. 2. THE PRESENT PROSPECTIVE, RANDOMIZED STUDY WAS CONDUCTED WITH 50 PATIENTS SUBMITTED TO CURATIVE ADJUVANT
IRRADIATION FOLLOWING TO SURGERY FOR MAMMARY CARCINOMA. THE RADIOTHERAPY WAS PERFORMED IN THE SAME WAY IN ALL PATIENTS WITH IRRADIATIONS OF THE THORACIC WALL AND THE REGIONAL LYMPH NODES. TWO GROUPS WERE BUILT BY RANDOMIZATION. THE STUDY GROUP
RECEIVED AN ADDITIONAL TREATMENT WITH ESBERITOX, THE CONTROL GROUP DID NOT RECEIVE AN ADDITIONAL TREATMENT. 3. AS A RESULT, NO PROTECTIVE INFLUENCE OF ESBERITOX COULD BE DEMONSTRATED. THE PARAMETERS INVESTIGATED WERE THE PERIPHERAL BLOOD COUNT
(LEUCOCYTES, GRANULOCYTES, LYMPHOCYTES, MONOCYTES, THROMBOCYTES, HEMOGLOBIN, HEMATOCRIT) AND THE INCIDENCE OF INFECTIONS. |